BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights Pharmaceutical Investing
LYNPARZA® in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer Life Science Investing
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences Pharmaceutical Investing
BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT Immunotherapy Treatment at SITC Annual Meeting Pharmaceutical Investing
Health Canada Approves Camzyos for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Pharmaceutical Investing
Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference Pharmaceutical Investing
AbbVie Presents Data from Extensive Portfolio at the American College of Rheumatology Convergence 2022 Pharmaceutical Investing
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. , Benefitfocus, Inc. , Abiomed, Inc. , Atlas Corp. Pharmaceutical Investing
